Patents by Inventor Stefan Schmidbauer

Stefan Schmidbauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES
    Publication number: 20200062863
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 27, 2020
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 10513560
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 24, 2019
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES
    Publication number: 20180134806
    Abstract: The invention relates to inhibitory anti-factor XII/FXIla antibodies and methods of their use.
    Type: Application
    Filed: November 27, 2017
    Publication date: May 17, 2018
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 9856326
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 9856325
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE
    Publication number: 20170209546
    Abstract: The present invention relates to pharmaceutical preparations comprising two-chain Factor VIII that are essentially free of Factor VIII-Light Chains (FVIII-LCs) which are not associated with Factor VIII-Heavy Chains (FVIII-HCs) having higher purity and which are less immunogenic. The invention also relates to methods to test the suitability of a pharmaceutical Factor VIII preparation and to methods to reduce in pharmaceutical Factor VIII preparations the amount of FVIII-HCs which are not associated with FVIII-LCs and/or of FVIII-LCs which are not associated with FVIII-HCs.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 27, 2017
    Applicant: CSL BEHRING GMBH
    Inventors: Stefan SCHMIDBAUER, Hubert METZNER, Lars ROBBEL
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170137536
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 18, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170121423
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
    Patent number: 9518127
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 13, 2016
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20140199361
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 17, 2014
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Therapeutic application of Kazal-type serine protease inhibitors
    Patent number: 8283319
    Abstract: The present invention relates to the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. The present invention also relates to the use of Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i.e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: October 9, 2012
    Assignee: CSL Behring GmbH
    Inventors: Stefan Schulte, Ulrich Kronthaler, Stefan Schmidbauer, Thomas Weimer, Kay Hofmann
  • THERAPEUTIC APPLICATION OF KAZAL-TYPE SERINE PROTEASE INHIBITORS
    Publication number: 20100279923
    Abstract: The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. In particular the present invention relates to the use of said Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors, in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e.
    Type: Application
    Filed: February 11, 2008
    Publication date: November 4, 2010
    Inventors: Stefan Schulte, Ulrich Kronthaler, Stefan Schmidbauer, Thomas Weimer, Kay Hofmann
  • Method for purifying enzymes from clostridium histolyticum using multi-stage chromatography
    Patent number: 7083964
    Abstract: The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum. It is provided for that the enzymes of the excess fermentation are separated by a multistage chromatography method by exclusively using chromatography materials on styrene/divinyl-benzene base and/or on base of in particular ceramic hydroxylapatite.
    Type: Grant
    Filed: June 1, 2002
    Date of Patent: August 1, 2006
    Assignee: Nordmark Arzneimittel GmbH & Co. KG
    Inventors: Manfred Kurfürst, Stefan Schmidbauer
  • Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
    Publication number: 20040137596
    Abstract: The invention relates to a method for purifying at least one enzyme obtained in an excess fermentation of Clostridium histolyticum.
    Type: Application
    Filed: November 21, 2003
    Publication date: July 15, 2004
    Inventors: Manfred Kurfrst, Stefan Schmidbauer